Kinetic reconstruction of the cancellous (Cn) and endocortical (Ec) remodelling unit reveals a net positive bone balance (BB) after 12 months of treatment with romosozumab

• Erik F. Eriksen,
• Rogely W. Boyce,
• Yifei Shi,
• Jacques P. Brown,
• Stéphane Horlait,
• Cesar Libanati,
• Roland Chapurlat,
• Pascale Chavassieux

Affiliations

Erik F. Eriksen

Oslo University Hospital, Department of Endocrinology- Morbid Obesity and Preventive Medicine, Oslo, Norway; Corresponding author.

Rogely W. Boyce

Amgen Inc., Department of Comparative Biology and Safety Sciences, Thousand Oaks- CA, United States

Yifei Shi

Amgen Inc., Global Biostatistical Science, Thousand Oaks- CA, United States

Jacques P. Brown

CHU de Quebec Research Centre and Laval University, Department of Medicine, Quebec, Canada

Stéphane Horlait

Amgen Inc., Bone Medical Strategy, Boulogne Billancourt, France

Cesar Libanati

UCB Pharma, Bone Medical Strategy, Brussels, Belgium

Roland Chapurlat

INSERM UMR 1033- Université de Lyon, Bone and Chronic Diseases, Lyon, France

Pascale Chavassieux

INSERM UMR 1033- Université de Lyon, Bone and Chronic Diseases, Lyon, France